Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide

समान संसाधन

• Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy
  द्वारा: Kleinberg, Lawrence
  प्रकाशित: (2016)
• Carmustine Wafer Implantation at the Era of Standardized Chemoradiation Protocol
  द्वारा: Roux, Alexandre, और अन्य
  प्रकाशित: (2019)
• Adverse Event with the Use of Carmustine Wafers and Postoperative Radiochemotherapy for the Treatment of High-grade Glioma
  द्वारा: Salle, Federico, और अन्य
  प्रकाशित: (2018)
• Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review
  द्वारा: Ashby, Lynn S., और अन्य
  प्रकाशित: (2016)
• A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
  द्वारा: Westphal, Manfred, और अन्य
  प्रकाशित: (2003)